0001209191-20-059528.txt : 20201119
0001209191-20-059528.hdr.sgml : 20201119
20201119190119
ACCESSION NUMBER: 0001209191-20-059528
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200601
FILED AS OF DATE: 20201119
DATE AS OF CHANGE: 20201119
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Graham G. Walmsley
CENTRAL INDEX KEY: 0001777517
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39712
FILM NUMBER: 201330035
BUSINESS ADDRESS:
STREET 1: ONE SANSOME STREET, SUITE 3630
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
BUSINESS PHONE: 415-801-8100
MAIL ADDRESS:
STREET 1: ONE SANSOME STREET, SUITE 3630
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Olema Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001750284
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 300409740
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 512 2ND STREET, 4TH FLOOR
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94107
BUSINESS PHONE: (415) 651-3316
MAIL ADDRESS:
STREET 1: 512 2ND STREET, 4TH FLOOR
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94107
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-06-01
0
0001750284
Olema Pharmaceuticals, Inc.
OLMA
0001777517
Graham G. Walmsley
C/O LOGOS GLOBAL MANAGEMENT LP
1 LETTERMAN DRIVE, BLDG. D, STE D3-700
SAN FRANCISCO
CA
94129
1
0
0
0
Series B Convertible Preferred Stock
2020-06-01
4
P
0
339578
4.7117
A
Common Stock
339578
339578
I
See Footnote
Series C Convertible Preferred Stock
2020-09-30
4
P
0
1183114
11.0623
A
Common Stock
1183114
1183114
I
See Footnote
Stock Option (Right to Buy)
19.00
2020-11-18
4
A
0
21520
0.00
A
2030-11-17
Common Stock
21520
21520
D
Stock Option (Right to Buy)
19.00
2020-11-18
4
A
0
21520
0.00
A
2030-11-17
Common Stock
21520
21520
D
Stock Option (Right to Buy)
19.00
2020-11-18
4
A
0
21520
0.00
A
2030-11-17
Common Stock
21520
21520
D
The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock are convertible into Common Stock on a 1:1 basis and have no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock will be automatically converted into shares of Common Stock.
The shares are held by Logos Opportunities Fund I L.P. ("Logos Fund I"). Logos Opportunies GP, LLC ("Logos GP") is the general partner of Logos Fund I and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
The shares are held by Logos Opportunities Fund II, L.P. ("Logos Fund II"). Logos GP is the general partner of Logos Fund II and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
The shares subject to the option vest in a series of 12 successive equal monthy installments measured from June 1, 2020, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.
The shares subject to the option vest in a series of 36 successive equal monthy installments measured from November 18, 2020, subject to the Reporting Person's continuous service through each applicable vesting date.
/s/ John B. Moriarty, Jr., Attorney-in-Fact
2020-11-19